Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer
Authors:
- 11 March 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 67 (1) , 69-73
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study GroupJournal of Clinical Oncology, 2008
- Optimal Chemotherapy Treatment for Women with Recurrent Ovarian CancerCurrent Oncology, 2007
- Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2007
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Role of gemcitabine in ovarian cancer treatmentAnnals of Oncology, 2006
- Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyGynecologic Oncology, 2004
- Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patientsLung Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958